Rocket Pharmaceuticals (RCKT) Accounts Payables (2014 - 2026)

Rocket Pharmaceuticals has disclosed Accounts Payables across 13 years of filings, most recently posting $21.5 million for Q1 2026.

• Accounts Payables for Q1 2026 came in at $21.5 million, down 33.58% year-over-year; the trailing twelve-month figure through Mar 2026 was $21.5 million (down 33.58% YoY), and the FY2025 annual result was $27.3 million, down 27.85% from the prior year.
• Accounts Payables came in at $21.5 million for Q1 2026 at Rocket Pharmaceuticals, down from $27.3 million in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $45.8 million in Q4 2023 to a low of $20.0 million in Q1 2022.
• The 5-year median for Accounts Payables is $30.6 million (2023), against an average of $31.3 million.
• Peak annual rise in Accounts Payables reached 86.9% in 2022, while the deepest fall reached 39.61% in 2022.
• Rocket Pharmaceuticals' Accounts Payables stood at $36.7 million in 2022, then rose by 24.9% to $45.8 million in 2023, then retreated by 17.39% to $37.8 million in 2024, then dropped by 27.85% to $27.3 million in 2025, then declined by 21.07% to $21.5 million in 2026.
• The last three Accounts Payables figures came in at $21.5 million (Q1 2026), $27.3 million (Q4 2025), and $28.3 million (Q3 2025), per Business Quant data.